![Andreas Herrmann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andreas Herrmann
Amministratore Delegato presso Alvotech Germany GmbH
Posizioni attive di Andreas Herrmann
Società | Posizione | Inizio | Fine |
---|---|---|---|
Alvotech Germany GmbH
![]() Alvotech Germany GmbH BiotechnologyHealth Technology Baliopharm GmbH operates as biotechnology company. It develops a novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer. The company was founded in 2011 and is headquartered in Juelich, Germany. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - | |
Baliopharm AG
![]() Baliopharm AG Miscellaneous Commercial ServicesCommercial Services Baliopharm AG operates as a biotechnology company. It develops a novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, psoriasis and multiple sclerosis and for cancer. The company was founded in 2011 and is headquartered in Basel, Switzerland. | Amministratore Delegato | 01/01/2011 | - |
3Z ehf
![]() 3Z ehf Investment ManagersFinance 3Z ehf engages in the provision of pharmaceuticals services. Its services include epilepsy, sleep, tailor made screening, acute toxicity, cardiovascular, and neurotox assays. The company was founded in by Karl Karlsson and Haraldur Þorsteinsson in 2008 and Is headquartered in Reykjavík, Iceland. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Andreas Herrmann
Precedenti posizioni note di Andreas Herrmann
Società | Posizione | Inizio | Fine |
---|---|---|---|
SYNIMMUNE GmbH
![]() SYNIMMUNE GmbH Miscellaneous Commercial ServicesCommercial Services Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million. | Fondatore | 07/07/2010 | - |
Statistiche
Distribuzione geografica
Germania | 3 |
Islanda | 2 |
Svizzera | 2 |
Posizioni
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Founder | 1 |
Settori
Commercial Services | 3 |
Health Technology | 2 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Alvotech Germany GmbH
![]() Alvotech Germany GmbH BiotechnologyHealth Technology Baliopharm GmbH operates as biotechnology company. It develops a novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer. The company was founded in 2011 and is headquartered in Juelich, Germany. | Health Technology |
3Z ehf
![]() 3Z ehf Investment ManagersFinance 3Z ehf engages in the provision of pharmaceuticals services. Its services include epilepsy, sleep, tailor made screening, acute toxicity, cardiovascular, and neurotox assays. The company was founded in by Karl Karlsson and Haraldur Þorsteinsson in 2008 and Is headquartered in Reykjavík, Iceland. | Finance |
Baliopharm AG
![]() Baliopharm AG Miscellaneous Commercial ServicesCommercial Services Baliopharm AG operates as a biotechnology company. It develops a novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, psoriasis and multiple sclerosis and for cancer. The company was founded in 2011 and is headquartered in Basel, Switzerland. | Commercial Services |
SYNIMMUNE GmbH
![]() SYNIMMUNE GmbH Miscellaneous Commercial ServicesCommercial Services Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million. | Commercial Services |
- Borsa valori
- Insiders
- Andreas Herrmann
- Esperienza